• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Ori Biotech, Fresenius Collaborate On Gene Therapy Manufacturing

    GLOBENEWSWIRE

    Fresenius Kabi Wins 2024 Novaplus Program Excellence Award

    BUSINESSWIRE

    CMS Grants Fresenius Kabi Q-Code and Payment Status for Tyenne®

    BUSINESSWIRE

    Fresenius Kabi Inducts 12 into National Blood Donation Hall of Fame

    BUSINESSWIRE

    Fresenius Kabi and Cellular Origins Collaborate on CGT Automation

    CONTRACTPHARMA

    Cellular Origins And Fresenius Kabi Sign Agreement For Gene Therapy

    BUSINESSWIRE

    Fresenius & Formycon Receive FDA Approval For Biosimilar Otulfi

    BUSINESSWIRE

    Fresenius Kabi USA`s Biologic Tyenne (Tocilizumab) Receives Suppl Approvals In US

    FDA

    Enforcement Report - Week of July 24, 2024

    FDA

    Fresenius Kabi USA Generic Naloxone Hydrochloride Receives Approval in the U.S.

    FDA

    Fresenius Kabi`s Tyenne (tocilizumab) Receives Approval in Europe

    EMA

    Fresenius Kabi`s Biologic Chorionic Gonadotropin Receives Approval in the U.S.

    FDA

    Metrodora Institute, Chooses the Ivenix Infusion System from Fresenius Kabi

    BUSINESSWIRE

    Fresenius Kabi Launches Single-Needle Option for the Amicus®

    BUSINESSWIRE

    Vizient Innovative Technology Contract Awarded to Fresenius Kabi for the Ivenix

    BUSINESSWIRE

    Enforcement Report - Week of January 25, 2023

    FDA

    Fresenius Kabi Deutschland`s Biologic Stimufend (pegfilgrastim) Receives Approval in Europe

    EMA

    Health Canada Issues Recall of Fresenius Kabi Canada Sodium Acetate Injection, USP: Particulate matter

    HEALTH CANADA

    Fresenius Kabi Issues Voluntary Recall of Sodium Acetate Injection, USP Due to the Presence of Particulate Matter

    FDA

    €250,000 Parenteral Nutrition Research Grant Awarded by Fresenius Kabi

    PRNEWSWIRE

    Enforcement Report - Week of October 6, 2021

    FDA

    Fresenius Kabi`s Generic Bortezomib Receives Tentative Approval in the U.S

    FDA

    Enforcement Report - Week of July 14, 2021

    FDA

    Fresenius Kabi Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection

    FDA

    Enforcement Report - Week of January 6, 2021

    FDA

    Enforcement Report - Week of December 30, 2020

    FDA

    Enforcement Report - Week of December 16, 2020

    FDA

    Enforcement Report - Week of December 2, 2020

    FDA

    Fresenius Kabi Issues Voluntary Nationwide Recall of a Single Lot of Dexmedetomidine Hydrochloride

    FDA

    Enforcement Report - Week of September 2, 2020

    FDA

    Enforcement Report - Week of July 22, 2020

    FDA

    Health Canada Issues Recall Fresenius Kabi Canada`s Dextrose 5% Injection

    FDA

    Fresenius Kabi`s Generic Icatibant Acetate Receives Approval in US

    FDA

    Enforcement Report - Week of June 17, 2020

    FDA

    Health Canada Isuues Recall of Fresenius Kabi Canada`s Penicillin G Sodium for Injection

    HEALTH CANADA

    Fresenius Kabi`s Recall of Ketorolac Results In QuVa Pharma® Recall of Compounded Sterile Product (R.E.C.K.)

    FDA

    Fresenius Kabi Issues Voluntary Nationwide Recall of 13 Lots of Ketorolac Tromethamine

    FDA

    Fresenius Kabi`s Generic Nafcillin Sodium Receives Approval in US

    FDA

    Fentanyl Billionaire No More: John Kapoor`s Net Worth Drops Below $1B

    FORBES

    Akorn fights to salvage Fresenius deal in appeal to Delaware Supreme Court

    FIERCE PHARMA

    Fresenius Kabi recalls Sodium Chloride Injection Due to Incorrect Labeling

    FDA

    Enforcement Report - Week of November 1, 2017

    FDA

    Enforcement Report - Week of April 19, 2017

    FDA

    Fresenius Kabi Sells German Oncology Compounding Business

    FRESENIUS KABI

    Claris Confirms Patent Challenge for Generic Propofol in US

    THE ECONOMIC TIMES

    Fresenius Kabi USA, LLC Initiated a Class II Voluntary Recall of Gentamicin Injection Due to Defective Container

    Fresenius Kabi USA, LLC Initiated a Class II Voluntary Recall of Cyanocobalamin Injection Due to Lack of Assurance of Sterility

    Fresenius Kabi USA, LLC Initiated a Class II Voluntary Recall of Ondansetron Injection Due to Lack of Assurance of Sterility

    Fresenius Kabi USA, LLC Initiated a Class II Voluntary Recall of Midazolam Hydrochloride Injection Due to Lack of Assurance of Sterility

    CytoSorbents Announces Initial Partnership with a Leading Global Cardiac Surgery Company

    PRESS RELEASE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.